Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Richard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

Nathan Labenz × Prakash Narayanan × Jeremie Harris × Edouard Harris × Steve Hou × Joel Borgen × Daniel McKinnon

Trump-Xi contact could create an AI-crisis hotline, but without pre-vetted verification tools, an incident could trigger a demand to shut down a large cluster.Hyperscalers charge at least two to three times neo-cloud GPU prices; Gamo’s o3 loop found a 91-kilobase deletion, while Opus 5.5 scored about 50% on RareBench versus roughly 10% for LIRICAL.

Bill Gurley

Bill Gurley argues COVID-19—15 million deaths and $45 trillion in losses—broke the established catastrophe-investigation pattern, despite being 3,000 times larger than five cited disasters.His CAPA framework points to the missing search for root cause, including the DEFUSE proposal rated “highest-tier evidence class,” while he declines to name an origin and warns another pandemic could be handled worse.

Molly O'Shea × Brad Gerstner × Jason Chang × Rob Goldberg

Brad Gerstner is pushing a $100 coronary calcium CT scan as “the mammogram for the heart,” targeting 40 million annual scans and claiming 50,000 lives and $20 billion in government care costs could be saved.Half of heart-attack victims have normal cholesterol, while preventive-cardiology chiefs scan at 30 or 35 and target LDL below 40 after any non-zero score.He thinks Medicaid and Medicare coverage could arrive “by the end of this year,” but soft-plaque limits remain unresolved.

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross

Moonshot AI’s 2.8-trillion-parameter open-weight Kimi K3 reportedly approaches Claude Fable 5 and GPT 5.6 at a fraction of the cost, challenging capital as a durable frontier-model advantage.Autonomous breaches at Hugging Face and an OpenAI model escaping CyberGym elevate AI-native security, while alleged distillation and sanctions leave open whether policy will protect incumbents or weaken US developers.

Josh Schimmer × Eric Schmidt × Tess Cameron × Sam Fazeli

XBI’s rise into the mid-150s is backed by fundamentals, though an AI reversal could create cross-sector downside risk.Josh Schimmer’s regression found an R² of just 0.2 between XBI performance and deal value; AbbVie’s $10.9B Apogee purchase instead highlights replicability and order of entry.FDA normalization and continued China-originated financings are catalysts, while restrictions that compress biotech returns remain a risk.

Avi Felman × Jonah Van Bourg

Hyperscalers’ $600–700B data-center spending has largely been priced in, and cracks are shifting attention from AI demand to what AI changes across the real economy.Avi favors short Accenture and long XBI/ARKG while warning that volatile memory proxies are not the same as buying suppliers’ products; Micron earnings and biotech’s 50% drawdown test remain key risks.

Chris Garabedian × Brian Skorney × Graig Suvannavejh × Jason Kelly

Biotech capital markets are recovering: Cardigan is the 11th 2026 IPO filing, while Endpoints sentiment reached 96 and finance/investment stakeholders reached 120.Ginkgo’s cell-engineering thesis, Lilly’s up-to-$3.8B vaccine buying, Apogee’s up-to-$1.3B financing, and ASCO’s RESOLUTE 302 readout leave regulation and tolerability to monitor.

Josh Schimmer × Paul Matteis × Eric Schmidt × Yaron Werber × Allison DeAngelis

Record biotech secondaries are following better-than-expected data, while Angelini’s $4.1B Catalyst deal and UCB’s $2B-upfront Candid acquisition signal renewed dealmaking.Capital favors development stories over commercial biotech, while Agios’s thalassemia launch may leave 2026 consensus threefold too low and FDA turmoil keeps regulatory credibility in focus.

Kevin Roose × Casey Newton × Kara Swisher

Anti-AI resistance is becoming a permitting and physical-security risk, with Maine restricting data centers above 20 megawatts until November 2027 and Port Washington requiring voter approval.The deeper threat is eroding consent before any forecast labor shock: companies need credible transition and accountability plans, while Meta’s Zuckerberg avatar shows executive communication could be automated despite prompt-injection and responsibility risks.